94 related articles for article (PubMed ID: 23362952)
1. Lysophosphatidic acid aberrancies and hepatocellular carcinoma: studies in the MDR2 gene knockout mouse.
Skill N; Wu J; Xu Y; Zhao Z; Maluccio M
Cancer Invest; 2013 Feb; 31(2):145-55. PubMed ID: 23362952
[TBL] [Abstract][Full Text] [Related]
2. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice.
Katzenellenbogen M; Pappo O; Barash H; Klopstock N; Mizrahi L; Olam D; Jacob-Hirsch J; Amariglio N; Rechavi G; Mitchell LA; Kohen R; Domany E; Galun E; Goldenberg D
Cancer Res; 2006 Apr; 66(8):4001-10. PubMed ID: 16618719
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.
Territo PR; Maluccio M; Riley AA; McCarthy BP; Fletcher J; Tann M; Saxena R; Skill NJ
BMC Med Imaging; 2015 May; 15():15. PubMed ID: 25981587
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice.
Katzenellenbogen M; Mizrahi L; Pappo O; Klopstock N; Olam D; Jacob-Hirsch J; Amariglio N; Rechavi G; Domany E; Galun E; Goldenberg D
Mol Cancer Res; 2007 Nov; 5(11):1159-70. PubMed ID: 18025261
[TBL] [Abstract][Full Text] [Related]
5. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis.
Potikha T; Stoyanov E; Pappo O; Frolov A; Mizrahi L; Olam D; Shnitzer-Perlman T; Weiss I; Barashi N; Peled A; Sass G; Tiegs G; Poirier F; Rabinovich GA; Galun E; Goldenberg D
Hepatology; 2013 Jul; 58(1):192-204. PubMed ID: 23423643
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice.
Barashi N; Weiss ID; Wald O; Wald H; Beider K; Abraham M; Klein S; Goldenberg D; Axelrod J; Pikarsky E; Abramovitch R; Zeira E; Galun E; Peled A
Hepatology; 2013 Sep; 58(3):1021-30. PubMed ID: 23526353
[TBL] [Abstract][Full Text] [Related]
7. Chronic liver inflammation and hepatocellular carcinogenesis are independent of S100A9.
De Ponti A; Wiechert L; Stojanovic A; Longerich T; Marhenke S; Hogg N; Vogel A; Cerwenka A; Schirmacher P; Hess J; Angel P
Int J Cancer; 2015 May; 136(10):2458-63. PubMed ID: 25331529
[TBL] [Abstract][Full Text] [Related]
8. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer.
Ikenaga N; Liu SB; Sverdlov DY; Yoshida S; Nasser I; Ke Q; Kang PM; Popov Y
Am J Pathol; 2015 Feb; 185(2):325-34. PubMed ID: 25478810
[TBL] [Abstract][Full Text] [Related]
9. Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model.
Potikha T; Pappo O; Mizrahi L; Olam D; Maller SM; Rabinovich GA; Galun E; Goldenberg DS
FASEB J; 2019 Jul; 33(7):7995-8007. PubMed ID: 30897344
[TBL] [Abstract][Full Text] [Related]
10. Implications of the lysophosphatidic acid signaling axis in liver cancer.
Lopane C; Agosti P; Gigante I; Sabbà C; Mazzocca A
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):277-282. PubMed ID: 28591560
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.
Panupinthu N; Lee HY; Mills GB
Br J Cancer; 2010 Mar; 102(6):941-6. PubMed ID: 20234370
[TBL] [Abstract][Full Text] [Related]
12. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts.
Mazzocca A; Dituri F; Lupo L; Quaranta M; Antonaci S; Giannelli G
Hepatology; 2011 Sep; 54(3):920-30. PubMed ID: 21674557
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma associated lipid metabolism reprogramming.
Skill NJ; Scott RE; Wu J; Maluccio MA
J Surg Res; 2011 Jul; 169(1):51-6. PubMed ID: 19932908
[TBL] [Abstract][Full Text] [Related]
14. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
15. Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver.
Ella E; Heim D; Stoyanov E; Harari-Steinfeld R; Steinfeld I; Pappo O; Perlman TS; Nachmansson N; Rivkin L; Olam D; Abramovitch R; Wege H; Galun E; Goldenberg D
Oncotarget; 2014 Nov; 5(21):10318-31. PubMed ID: 25401338
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression.
Park SY; Jeong KJ; Panupinthu N; Yu S; Lee J; Han JW; Kim JM; Lee JS; Kang J; Park CG; Mills GB; Lee HY
Oncogene; 2011 Mar; 30(11):1351-9. PubMed ID: 21102517
[TBL] [Abstract][Full Text] [Related]
17. Lysophospholipid variants in hepatocellular carcinoma.
Skill NJ; Jianmin W; Yan X; Zhao Z; Tector AJ; Maluccio MA
J Surg Res; 2013 Jun; 182(2):241-9. PubMed ID: 23158405
[TBL] [Abstract][Full Text] [Related]
18. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice.
Pusterla T; Nèmeth J; Stein I; Wiechert L; Knigin D; Marhenke S; Longerich T; Kumar V; Arnold B; Vogel A; Bierhaus A; Pikarsky E; Hess J; Angel P
Hepatology; 2013 Jul; 58(1):363-73. PubMed ID: 23504974
[TBL] [Abstract][Full Text] [Related]
19. The ins and outs of lysophosphatidic acid signaling.
Moolenaar WH; van Meeteren LA; Giepmans BN
Bioessays; 2004 Aug; 26(8):870-81. PubMed ID: 15273989
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid enhances human hepatocellular carcinoma cell migration, invasion and adhesion through P38 MAPK pathway.
Zhu B; Shi S; Ma YG; Fan F; Yao ZZ
Hepatogastroenterology; 2012 May; 59(115):785-9. PubMed ID: 22020916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
